Literature DB >> 23207686

TROP2 correlates with microvessel density and poor prognosis in hilar cholangiocarcinoma.

Shanglei Ning1, Sen Guo, Jianjun Xie, Yunfei Xu, Xiaofei Lu, Yuxin Chen.   

Abstract

BACKGROUND: Trophoblast cell surface antigen 2 (TROP2) was found to be associated with tumor progression and poor prognosis in a variety of epithelial carcinomas. The aim of the study was to investigate TROP2 expression and its prognostic impact in hilar cholangiocarcinoma.
METHODS: Immunohistochemistry and quantitative real-time PCR were used to determine TROP2 expression in surgical specimens from 70 hilar cholangiocarcinoma patients receiving radical resection. The relationship between TROP2 expression and microvessel density was investigated and standard statistical analysis was used to evaluate TROP2 prognosis significance in hilar cholangiocarcinoma.
RESULTS: High TROP2 expression by immunohistochemistry was found in 43 (61.4 %) of the 70 tumor specimens. Quantitative real-time PCR confirmed that TROP2 level in tumor was significantly higher than in non-tumoral biliary tissues (P = 0.001). Significant correlations were found between TROP2 expression and histological differentiation (P = 0.016) and tumor T stage (P = 0.031) in hilar cholangiocarcinoma. TROP2 expression correlated with microvessel density in hilar cholangiocarcinoma (P = 0.026). High TROP2 expression patients had a significantly poorer overall survival rate than those with low TROP2 expression (30 vs. 68.5 %, P = 0.001), and multivariate Cox regression analysis indicated TROP2 as an independent prognostic factor for hilar cholangiocarcinoma (P = 0.004).
CONCLUSION: TROP2 expression correlates with microvessel density significantly and is an independent prognostic factor in human hilar cholangiocarcinoma.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23207686     DOI: 10.1007/s11605-012-2105-1

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  41 in total

1.  Extent of tumor vascularization correlates with prognosis and hematogenous metastasis in gastric carcinomas.

Authors:  N Tanigawa; H Amaya; M Matsumura; T Shimomatsuya; T Horiuchi; R Muraoka; M Iki
Journal:  Cancer Res       Date:  1996-06-01       Impact factor: 12.701

Review 2.  Endoscopic management of hilar cholangiocarcinoma.

Authors:  Andrea Parodi; Deborah Fisher; Marc Giovannini; Todd Baron; Massimo Conio
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-01-24       Impact factor: 46.802

3.  Angiogenesis and clinicopathologic characteristics in different hepatocellular carcinoma subtypes defined by EpCAM and α-fetoprotein expression status.

Authors:  Yun-feng Shan; Yuan-lan Huang; Yuan-kang Xie; Yan-he Tan; Bi-Cheng Chen; Men-tao Zhou; Hong-qi Shi; Zheng-ping Yu; Qi-tong Song; Qi-yu Zhang
Journal:  Med Oncol       Date:  2010-06-23       Impact factor: 3.064

4.  Liver resections for hilar cholangiocarcinoma.

Authors:  F Giuliante; F Ardito; M Vellone; G Nuzzo
Journal:  Eur Rev Med Pharmacol Sci       Date:  2010-04       Impact factor: 3.507

5.  Recurrence-free long-term survival after liver transplantation in patients with 18F-FDG non-avid hilar cholangiocarcinoma on PET.

Authors:  A Kornberg; B Küpper; K Thrum; J Wilberg; A Sappler; D Gottschild
Journal:  Am J Transplant       Date:  2009-09-22       Impact factor: 8.086

6.  Natural History and Prognostic Factors of Advanced Cholangiocarcinoma without Surgery, Chemotherapy, or Radiotherapy: A Large-Scale Observational Study.

Authors:  Jongha Park; Myung-Hwan Kim; Kyu-Pyo Kim; Do Hyun Park; Sung-Hoon Moon; Tae Jun Song; Junbum Eum; Sang Soo Lee; Dong Wan Seo; Sung Koo Lee
Journal:  Gut Liver       Date:  2009-12-31       Impact factor: 4.519

7.  Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.

Authors:  Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

Review 8.  Angiogenesis: an organizing principle for drug discovery?

Authors:  Judah Folkman
Journal:  Nat Rev Drug Discov       Date:  2007-04       Impact factor: 84.694

9.  Surgical management and prognostic factors of hilar cholangiocarcinoma: experience with 115 cases in China.

Authors:  Liu Yubin; Fang Chihua; Jian Zhixiang; Ou Jinrui; Liu Zixian; Zheng Jianghua; Lin Ye; Jin Haosheng; Lu Chaomin
Journal:  Ann Surg Oncol       Date:  2008-06-11       Impact factor: 5.344

Review 10.  The emerging role of EpCAM in cancer and stem cell signaling.

Authors:  Markus Munz; Patrick A Baeuerle; Olivier Gires
Journal:  Cancer Res       Date:  2009-07-07       Impact factor: 12.701

View more
  14 in total

1.  A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors.

Authors:  Gentry T King; Keith D Eaton; Brandon R Beagle; Christopher J Zopf; Gilbert Y Wong; Heike I Krupka; Steven Y Hua; Wells A Messersmith; Anthony B El-Khoueiry
Journal:  Invest New Drugs       Date:  2018-01-15       Impact factor: 3.850

2.  The Role of TROP2 in BCC and Cutaneous SCC: A Clinical and Immunohistochemical Study.

Authors:  Azza Gaber Antar Farag; Hala Said El-Rebey; Mohamed Abd El-Moneim Shoeib; Shimaa Mohammed Ahmed El-Fiky; Mustafa Elsayed Elshaib; Amal Farid Mostafa
Journal:  Clin Cosmet Investig Dermatol       Date:  2021-06-01

3.  FBXW7 suppresses epithelial-mesenchymal transition, stemness and metastatic potential of cholangiocarcinoma cells.

Authors:  Hui Yang; Xiaofei Lu; Ziming Liu; Lili Chen; Yunfei Xu; Yuli Wang; Guangwei Wei; Yuxin Chen
Journal:  Oncotarget       Date:  2015-03-20

Review 4.  Trop2 and its overexpression in cancers: regulation and clinical/therapeutic implications.

Authors:  Anna Shvartsur; Benjamin Bonavida
Journal:  Genes Cancer       Date:  2015-03

Review 5.  Impact of TROP2 expression on prognosis in solid tumors: A Systematic Review and Meta-analysis.

Authors:  Ping Zeng; Min-Bin Chen; Li-Na Zhou; Min Tang; Chao-Ying Liu; Pei-Hua Lu
Journal:  Sci Rep       Date:  2016-09-20       Impact factor: 4.379

6.  The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms.

Authors:  Haiyan Liu; Jianhui Shi; Fan Lin
Journal:  Appl Immunohistochem Mol Morphol       Date:  2017-09

7.  Cullin 4A is associated with epithelial to mesenchymal transition and poor prognosis in perihilar cholangiocarcinoma.

Authors:  Tong-Jun Zhang; Dong Xue; Cheng-De Zhang; Ze-Dong Zhang; Qing-Ran Liu; Jian-Qiang Wang
Journal:  World J Gastroenterol       Date:  2017-04-07       Impact factor: 5.742

8.  Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway.

Authors:  Ting Liu; Yueyang Liu; Xiangxiang Bao; Jiguang Tian; Yang Liu; Xingsheng Yang
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

9.  Expression of tumor-associated calcium signal transducer 2 in patients with salivary adenoid cystic carcinoma: Correlation with clinicopathological features and prognosis.

Authors:  Yichao Xia; Bo Li; Ning Gao; Hui Xia; Yi Men; Ying Liu; Zhe Liu; Qianming Chen; Longjiang Li
Journal:  Oncol Lett       Date:  2014-07-31       Impact factor: 2.967

10.  Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.

Authors:  Peng Xu; Yang Zhao; Kang Liu; Shuai Lin; Xinghan Liu; Meng Wang; Pengtao Yang; Tian Tian; Yu-Yao Zhu; Zhijun Dai
Journal:  Cancer Manag Res       Date:  2017-12-12       Impact factor: 3.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.